89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Revenue of 89bio, Inc. (ETNB)
Revenue in 2023 (TTM): $
According to 89bio, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of 89bio, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-273,000 | $-134,463,000 | $-138,322,000 | $-142,189,000 |
| 2022 | $ | $-240,000 | $-99,845,000 | $-102,007,000 | $-102,026,000 |
| 2021 | $ | $-79,000 | $-90,190,000 | $-90,269,000 | $-90,122,000 |
| 2020 | $ | $-60,000 | $-49,498,000 | $-49,558,000 | $-49,499,000 |
| 2019 | $ | $-17,000 | $-57,185,000 | $-57,202,000 | $-57,420,000 |
| 2018 | $ | $-6,000 | $-16,142,000 | $-16,148,000 | $-16,176,000 |